By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Jarden Corp
Stock ticker JAH
Live stock price [stckqut]JAH[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $94.95
Target stock price (averages with growth) $119.91
Target stock price (averages with no growth) $94.36
Target stock price (manual assumptions) $76.43

The following company description is from Google Finance: http://www.google.com/finance?q=jah

Jarden Corporation (Jarden) is a global consumer products company. The Company operates in three segments through a range of brands, including: Outdoor Solutions: Abu Garcia, Aero, Berkley, Campingaz, Coleman, ExOfficio, Fenwick, Gulp!, K2, Marker, Marmot, Mitchell, Penn, Rawlings, Shakespeare, Stearns, Stren, Trilene, Volkl and Zoot; Consumer Solutions: Bionaire, Crock-Pot, FoodSaver, Health o meter, Holmes, Mr. Coffee, Oster, Patton, Rival, Seal-a-Meal, Sunbeam, VillaWare and White Mountain, and Branded Consumables: Ball, Bee, Bernardin, Bicycle, Billy Boy, Crawford, Diamond, Dicon, Fiona, First Alert, First Essentials, Hoyle, Kerr, Lehigh, Lillo, Loew-Cornell, Mapa, NUK, Pine Mountain, Quickie, Spontex and Tigex. On December 31, 2012, American Capital Ltd sold its portfolio company Lifoam Holdings, Inc. to the Company. In October 2013, Jarden Corporation completed its acquisition of Yankee Candle Investments LLC from a fund managed by Madison Dearborn Partners, LLC.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Jarden Corp.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

Stock price at the time of the calculation: $61.52

Growth: 0.15

Current EPS (TTM): $1.8

P/E: 34

Future EPS Calc: $3.62

Future Stock Price Calc: $123.09

Target stock price: $76.43

I hope that this makes you a better investor. [/s2If]

By:
On:
In: Poor company, Stock analysis
Tagged:
With: 0 Comments

Company name Allscripts Healthcare Solutions Inc
Stock ticker MDRX
Live stock price [stckqut]MDRX[/stckqut]
Confident Investor Rating Poor

The following company description is from Google Finance: http://www.google.com/finance?q=mdrx

Allscripts Healthcare Solutions, Inc. (Allscripts) is a provider of clinical, financial, connectivity and information solutions and related professional services to hospitals, physicians and post-acute organizations. The Company provides a variety of integrated clinical software applications for hospitals, physician practices and post-acute organizations. For hospitals and health systems these applications include its Sunrise Enterprise suite of clinical solutions, consisting of a range of acute care Electronic Health Record (EHR), integrated with financial/administrative solutions, including performance management and revenue cycle/access management. The Company’s acute care solutions include Emergency Department Information System (EDIS), care management and discharge management. On February 24, 2011, Misys plc (Misys) disposed of its remaining interest in Allscripts. Effective March 5, 2013, Allscripts Healthcare Solutions Inc acquired Jardogs LLC. and dbMotion Ltd.
Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in Allscripts Healthcare Solutions Inc. It is not possible to confidently invest in a company that is not currently profitable.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

By:
On:
In: Poor company, Stock analysis
Tagged:
With: 0 Comments

 

Company name RadNet Inc.
Stock ticker RDNT
Live stock price [stckqut]RDNT[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Fair
EPS growth Good
P/E growth Poor
EBIT growth Poor

ANALYSIS

Confident Investor Rating Poor
Target stock price (TWCA growth scenario) $2.92
Target stock price (averages with growth) $0.19
Target stock price (averages with no growth) $0.19
Target stock price (manual assumptions) $1.88

The following company description is from Google Finance: http://www.google.com/finance?q=rdnt

RadNet, Inc. (RadNet) is engaged in providing freestanding, fixed-site outpatient diagnostic imaging services in the United States. The Company’s services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. On November 7, 2011, the Company completed the acquisition of all outstanding equity interests in Raven Holdings U.S., Inc. In November 2011, the Company acquired 21 imaging facilities in Maryland, Delaware and Rhode Island, consisting of the majority of the United States imaging operations of CML HealthCare Inc. (CML). On August 1, 2011, the Company completed the acquisition of a multi-modality imaging center located in San Jacinto, California from San Jacinto Imaging, LLC. On February 18, 2011, the Company completed the acquisition of Team Radiology, Inc. On December 31, 2012, it acquired Lenox Hill Radiology.

 

Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in RadNet Inc.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

Stock price at the time of the calculation: $1.9

Growth: 0.1

Current EPS (TTM): $1.34

P/E: 1.4

Future EPS Calc: $2.15

Future Stock Price Calc: $3.02

Target stock price: $1.87

I hope that this makes you a better investor. [/s2If]

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name St. Jude Medical, Inc.
Stock ticker STJ
Live stock price [stckqut]STJ[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Poor
EPS growth Fair
P/E growth Good
EBIT growth Poor

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $65.79
Target stock price (averages with growth) $80.45
Target stock price (averages with no growth) $71.36
Target stock price (manual assumptions) $67.23

The following company description is from Google Finance: http://www.google.com/finance?q=stj

St. Jude Medical, Inc. (St. Jude) develops, manufactures and distributes cardiovascular medical devices. Its principal products in each therapy area are: Cardiac Rhythm Management – tachycardia implantable cardioverter defibrillator systems (ICDs) and bradycardia pacemaker systems (pacemakers); Cardiovascular – vascular products, which include vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories, and structural heart products, which include heart valve replacement and repair products and structural heart defect devices; Atrial Fibrillation – electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems, and Neuromodulation – neurostimulation products, which include spinal cord and deep brain stimulation devices. In August 2013, St. Jude Medical Inc announced the acquisition of Endosense SA.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in St. Jude Medical, Inc. as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

Stock price at the time of the calculation: $67.02

Growth: 0.1

Current EPS (TTM): $2.49

P/E: 27

Future EPS Calc: $4.01

Future Stock Price Calc: $108.27

Target stock price: $67.23

I hope that this makes you a better investor. [/s2If]